<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471948</url>
  </required_header>
  <id_info>
    <org_study_id>Si379/2019</org_study_id>
    <nct_id>NCT04471948</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of 1064-nm Picosecond Laser With Microlens Array for Pore Tightening; a Pilot Study</brief_title>
  <official_title>The Safety and Efficacy of 1064-nm Picosecond Laser 1064 With Microlens Array for Pore Tightening; a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of 1064-nm Picosecond
      laser 1064 With Microlens Array for Pore tightening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Safety and Efficacy of Picosecond laser 1064 Nanometers With Microlens Array for Pore
      tightening; a Pilot Study Primary outcome : pore size Secondary outcome : side effect,
      patient satisfaction, global evaluation the patient recieved laser treament once a month for
      3 months and then follow up after last treatment at 1, 3 ,6 month

      Enlarged facial pores is one of the skin signs in photoaging. There are 3 major clinical
      causes of enlarged facial pores: highs sebum excretion, decreased elasticity around pores and
      increased hair follicle volume. Possible causative factors of enlarged facial pores include
      many exogenous and endogenous factors include genetic predisposition, seborrhea and chronic
      ultraviolet light exposure. Picosecond laser are new device which has been used in skin
      rejuvenation. The main mechanism of action is laser induced optical breakdown (LIOB).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2020</start_date>
  <completion_date type="Anticipated">December 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pore size by Antera 3D image</measure>
    <time_frame>change from baseline in pore size at 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Enlarged Pores</condition>
  <arm_group>
    <arm_group_label>Fractional picosecond laser 1,064 nm laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 arm The subjects with enlarged pores were treated with fractional picosecond laser 1,064 nm laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractional picosecond 1064 nm laser</intervention_name>
    <description>The parameter of laser was 8 mm spot size, 0.8 mJ/CM2, 750 ps, 5 Hz, 2 passes The treatment was done in every 4 weeks for 3 sessions.</description>
    <arm_group_label>Fractional picosecond laser 1,064 nm laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both male and female age 25-40 years

          -  No underlying disease

        Exclusion Criteria:

          -  History of retinoid or other keratolytic drugs used within 6 months before enrolled

          -  History of keloid

          -  photosensitivity

          -  Immunocompromised host
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>woraphong Manuskiatti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>woraphong Manuskiatti, M.D.</last_name>
    <phone>02-419-1000</phone>
    <email>doctorlaser@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Siriwan palawisuth, M.D.</last_name>
    <phone>02-419-1000</phone>
    <email>siriwan_monk@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology, Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woraphong Manuskiatti, M.D.</last_name>
      <phone>081-915-0555</phone>
      <email>doctorlaser@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Siriwan Palawisuth, M.D.</last_name>
      <phone>089-022-4215</phone>
      <email>siriwan_monk@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Woraphong Manuskiatti, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rungsima Wanitphakdeedacha, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Siriwan Palawisuth, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chalermkwan Apinuntham, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 11, 2020</last_update_submitted>
  <last_update_submitted_qc>July 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Woraphong Manuskiatti, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

